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Objective/Background: Sickle cell disease is a hereditary hemoglobinopathy characterized by
abnormal hemoglobin production, hemolytic anemia, and intermittent occlusion of small blood
vessels, leading to tissue ischemia, chronic organ damage, and organ dysfunction including
endocrine organs. The aim of this work was to evaluate some gonadal hormones in female
children with sickle cell anemia (SCA) in correlation with iron overload.
Methods: This study was conducted on 40 female children with SCA with a serum ferritin
of > 1000 ng/mL, who were attendants at the Hematology Unit, Pediatric Department, Tanta
University, Tanta, Egypt in the period from May 2012 to April 2014. Their ages ranged from
11 years to 15 years and the mean age value was 12.63 ± 1.36 years (Group I). Forty female chil-
dren with SCA of matched age with no iron overload served as a control Group (Group II). For all
patients in Groups I and II the following were performed/assessed: complete blood count,
hemoglobin electrophoresis, serum iron status, serum estrogen, luteinizing hormone (LH),
and follicle-stimulating hormone (FSH).
Results: There were significantly higher serum ferritin and serum iron levels and significantly
lower total iron binding capacity, FSH, LH, and estrogen levels in Group I compared with Group
II (mean serum ferritin was 2635.1 ± 918.9 in Group I vs. 292.55 ± 107.2 in Group II with a p
value of .001; mean serum iron was 196.3 ± 55.6 in Group I vs. 120 ± 16.57 in Group II with a
p value of .001 and mean serum total iron binding capacity was 247.3 ± 28.6 in Group I vs.
2 A.A. Hagag et al.327.8.7 ± 21.96 in Group II with a p value of .001; mean FSH level was 1.36 ± 0.22 mIU/mL in
Group I vs. 2.64 ± 0.81 mIU/mL in Group II with a p value of .021; mean LH level was 0.11
± 0.006 mIU/mL in Group I vs. 1.78 ± 1.12 mIU/mL in Group II with a p value of .003; mean
estrogen level was 21.45 ± 10.23 pg/mL in Group I vs. 42.36 ± 15.44 pg/mL in Group II with a
p value of 0.001) with significant negative correlation between serum gonadal hormones and
serum ferritin (r =  .835 and p value of .01 for FSH and serum ferritin; r =  .597 and a p value
of .01 for LH and serum ferritin; and r =  0.624 and p value of .01 for estrogen and serum
ferritin.
Conclusion: Female patients with SCA with iron overload may have gonadal hormone deficiency
with significant negative correlations between gonadal hormones including FSH, LH, estrogen,
and serum ferritin. Recommendations include regular iron chelation for prevention of irre-
versible damage of the ovaries and attaining normal sexual maturation, and regular follow
up for females with SCA with assessment of puberty as they are more vulnerable to develop
hypogonadism and may require hormonal replacement therapy.
 2015 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Sickle cell disease (SCD) is a hereditary hemoglobinopathy
characterized by abnormal sickle hemoglobin (HbS) produc-
tion, hemolytic anemia, and intermittent occlusion of small
blood vessels, leading to acute and chronic tissue ischemia,
chronic organ damage, and organ dysfunction including
endocrine organs [1]. HbS is common and clinically signifi-
cant structural hemoglobin variant [2].
HbS is caused by a mutation in the b-globin gene in which
the 17th nucleotide is changed from thymine to adenine and
the sixth amino acid in b-globin chain is changed to valine
instead of glutamic acid; this mutation produces hydropho-
bic motif in the deoxygenated HbS tetramer that results in
binding between b1 and b2 chains of two hemoglobin mole-
cules. This crystallization produces a polymer nucleus,
which grows and fills the erythrocyte, disrupting its archi-
tecture and flexibility and promoting cellular dehydration,
with physical and oxidative cellular stress [3].
Endocrine dysfunction is commonly encountered in
hematological diseases like thalassemia and SCD. The phys-
iopathology of endocrine organ pathology is not clear in
patients with SCD; however, iron storage due to recurrent
and frequent transfusions, or ischemia due to vaso-
occlusive crises and inflammatory mediators during ische-
mia are proposed as the main reasons for endocrine dys-
functions [4].
The prevalence of endocrine complications among
children with sickle-cell anemia (HbSS) varies in different
populations depending on the literacy rate, socio-
economic status, availability of regular chelation therapy,
and transfusions [5].
Gonadal iron deposition and gonadal damage due to iron
overload is an irreversible process even if the iron level is
corrected at a later stage of the SCD [6]. This reflects the
importance of early and regular use of iron chelators for
prevention of irreversible damage of the ovaries and attain-
ing normal sexual maturation and the necessity of regular
follow up for gonadal hormones with assessment of puberty
as females with thalassemia and SCA are more vulnerable to
develop hypogonadism and may be in need of hormonalreplacement therapy to be capable of achieving pregnancy
[7]. The aim of this work was to evaluate some gonadal
functions in females with HbSS.
Material and methods
This study was done after the approval from the Ethical
Committee of the Research Center of Tanta University,
Tanta, Egypt and parental consent was received for all chil-
dren included in this study. The study was carried out on 40
females with HbSS who were attendants at the Hematology
Unit, Pediatric Department, Tanta University in the period
from May 2012 to April 2014, whose ages ranged from 11
years to 15 years and the mean age value was 12.63 ± 1.36
years (Group I), and 40 female children with HbSS with ages
ranging from 11 years to 15 years and with a mean age value
of 12.22 ± 1.13 years with no iron overload as a control
group (Group II).
This study included females with HbSS with serum fer-
ritin of >1000 ng/mL (with iron overload) that came to our
Hematology Center within a 2-year period of the study (40
female patients).
Females with HbSS under hormonal therapy were
excluded from this study.
All patient and control Groups were subjected to the fol-
lowing: (a) complete history taking; (b) thorough clinical
examination with special attention to anthropometric mea-
surements including weight and height, pallor, jaundice,
splenomegaly, hepatomegaly, and Tanner staging for
assessment of puberty [8]; and (c) laboratory investigations.
Specimen collection and handling
Five milliliters of venous blood were collected using sterile
needles through gentle venipuncture after sterilization of
the puncture site with alcohol, and collected samples were
divided into: (a) 2 mL in 20 lL ethylenediaminetetraacetic
acid solution for complete blood count including differential
white blood cells count which was done on a Leishman
stained peripheral blood smear with evaluation using an
ERMA PCE-210 N cell counter (fully automated blood cells
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trophoresis [10], and (b) 3 mL in a plain tube that allowed
for clotting in a water bath at 37 C. After clotting, centrifu-
gation was done at 1500g for 10 min. Separated serum was
collected in three tubes. The first tube was for assessment
of serum iron and iron binding capacity, the second tube
for assessment of serum ferritin, and the third for assess-
ment of FSH, LH, and estrogen serum levels [11–16].
Chelation therapy
All patients were treated with deferasirox, 20–30 mg/kg/d
once daily, preferably before meals [17], but in patients
with persistently high serum ferritin levels above 3000 ng/
mL, deferasirox was combined with desferrioxamine,
20–40 mg/kg in 8–12 h subcutaneous infusion using an
infusion pump [17] or continuous intravenous infusion for
8–10 h per day for 10 days per month [18].
Statistical analysis
Statistical analysis of the present study was conducted using
mean, standard error, Student t test, chi-square test, linear
correlation coefficient test with SPSS version 17 (SPSS Inc.,
Chicago, IL, USA).
Results
There were no statistically significant differences between
Groups I and II with regards to age and clinical presentation
including pallor, jaundice, hepatomegaly, acute chest
syndrome, and sickle cell crisis, but there were significantTable 1 Comparison between Group I and Group II regarding cli
Clinical data Group I (n = 40)
Age (y)
Range 11–15
Mean ± SD 12.63 ± 1.36
Pallor 32 (80)
Jaundice 33 (82.5)
Hepatomegaly 15 (37.5)
Acute chest syndrome 3 (7.5)
Leg ulcers 2 (5)
Sickle cell crisis 23 (57.5)
Age of 1st transfusion (mo)
Range 14–76
Mean ± SD 22 ± 10.25
Frequency of blood transfusion
Every 2 wk 5 (12.5)
Every 3–4 wk 14 (35)
>4 wk 21 (52.5)
Interval of transfusion (wk)
Range 2–20
Mean 6.2 ± 2.8
Note. Data are presented as n (%), unless otherwise indicated. SD = st
* Significant.differences between Groups I and II regarding transfusion
regimen (Table 1).
There were normocytic normochromic anemia with retic-
ulocytosis, leukocytosis, and thrombocytosis in studied
patients of HbSS of both groups with no statistically signifi-
cant differences between Groups I and II regarding hemoglo-
bin level, mean corpuscular volume, mean corpuscular
hemoglobin, mean corpuscular hemoglobin concentration,
reticulocytes, platelets, and white blood cell counts
(Table 2).
There were significant differences regarding tanner stag-
ing with delayed puberty according to tanner staging in
Group I compared with Group II (Table 3).
There were significantly higher serum ferritin and serum
iron and significantly lower total iron binding capacity, FSH,
LH, and estrogen levels in Group I compared with Group II
(mean serum ferritin was 2635.1 ± 918.9 in Group I vs.
292.55 ± 107.2 in Group II with a p value of .001; mean
serum iron was 196.3 ± 55.6 in Group I vs. 120 ± 16.57 in
Group II with a p value of .001 and mean serum total iron
binding capacity was 247.3 ± 28.6 in Group I vs. 327.8.7
± 21.96 in Group II with a p value of .001; mean FSH level
was 1.36 ± 0.22 mIU/mL in Group I vs. 2.64 ± 0.81 mIU/mL
in Group II with a p value of .021; mean LH level was 0.11
± 0.006 mIU/mL in Group I vs. 1.78 ± 1.12 mIU/mL in Group
II with a p value of .003; mean estrogen level was 21.45
± 10.23 pg/mL in Group I vs. 42.36 ± 15.44 pg/mL in Group
II with a p value of .001; Table 4).
There were significant negative correlations between
serum FSH, LH, estrogen, and serum ferritin (Figures. 1–
3). In this study iron overload was found to be a significant
cause of hypogonadism in Group I using univariate analysis
(see Table 5).nical data.
Group II (n = 40) p
11–15
12.22 ± 1.13 .74
30 (75) .73
28 (70) .082
16 (40) .91
4 (10) .72
4 (10) .077
20 (50) .086
23–96
60 ± 11.33 .012*
1 (2.5)
2 (5) .042*
37 (92.5)
2–45
20.2 ± 6.6 .031*
andard deviation.
Table 2 Comparison between group I and group II regarding complete blood count.
Parameters Group I (n = 40) Group II (n = 40) p
Hemoglobin (g/dL) Range 4.1–10.3 6–11 .081
Mean ± SD 8.01 ± 1.22 8.15 ± 1.32
Red blood cells (million/mm3) Range 1.96–4.4 2.22–3.9 .55
Mean ± SD 3.19 ± 0.89 3.16 ± 0.92
Mean corpuscular volume (fL) Range 73–99 74.5–100 .65
Mean ± SD 86.9 ± 11.1 85.62 ± 6.85
Mean corpuscular hemoglobin (pg) Range 26–30 27–33 .70
Mean ± SD 28.2 ± 1.62 29.61.5 ± 1.68
Mean corpuscular hemoglobin concentration (%) Range 31–34 30–33 .83
Mean ± SD 32.2 ± 1.32 30.9 ± 1.29
Platelets (thousands/mm3) Range 160–688 150–430 .71
Mean ± SD 359.6 ± 32.45 362 ± 18.75
Total leucocytic count (thousands/mm3) Range 8–20 7–18 .07
Mean ± SD 14.9 ± 3.291 13.95 ± 2.39
Reticulocytes % Range 1.8–9 1.6–8 .66
Mean ± SD 4.8 ± 1.98 4.63 ± 0.79
Note. SD = standard deviation.
Table 3 Tanner staging of studied patients and controls.
Group I (n = 40) Group II (n = 40) v2 p
Tanner staging
Tanner 1 12 (30%) 10 (20%)
Tanner 2 16 (40%) 6 (10%)
Tanner 3 10 (25%) 12 (30%) 4.456 .033*
Tanner 4 2 (5%) 9 (40%)
Tanner 5 0 (0%) 3 (0%)
* Significant (p < 0.05).
Table 4 Serum gonadal hormones and iron status in studied patients and controls.
Parameters Group I (n = 40) Group II (n = 40) t p
Follicle stimulating hormone (mIU/mL)
Range 0.3–1.7 1.2–3.7
Mean ± SD 1.36 ± 0.22 2.64 ± ± 0.81 3.11 .021*
Luteinizing hormone (mIU/mL)
Range 0.1–0.15 0.2–3.4
Mean ± SD 0.11 ± 0.006 1.78 ± 1.12 5.21 .003*
Serum estrogen (pg/mL)
Range 7–50 22.4–69.4
Mean ± SD 21.45 ± 10.23 42.36 ± 15.44 8.27 .001*
Serum ferritin (ng/mL)
Range 1155–4500 235–435
Mean ± SD 2635.1 ± 918.9 292.55 ± 107.2 7.42 .001*
Serum iron (lg/mL)
Range 115–321 90–140
Mean ± SD 196.3 ± 55.6 120 ± 16.57 4.48 .001*
Serum TIBC (lg/mL)
Range 180–302 275–366
Mean ± SD 247.3 ± 28.6 327.8.7 ± 21.96 12.31 .001*
Note. SD = standard deviation; TIBC = total iron binding capacity.
* Significant.
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Figure 1 Correlation between serum ferritin and serum
follicle-stimulating hormone. There was significant negative
correlations between serum ferritin and serum follicle-stimu-
lating hormone in the studied patients. Note. FSH = follicle-
stimulating hormone.
Figure 2 Correlation between serum ferritin and serum
luteinizing hormone. There were significant negative correla-
tions between serum ferritin and serum luteinizing hormone in
the studied patients. Note. LH = luteinizing hormone.
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Figure 3 Correlation between serum ferritin and serum
estrogen. There were significant negative correlations between
serum ferritin and serum estrogen in the studied patients.
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SCD is an inherited disorder, characterized by defective
hemoglobin synthesis with production of HbS. Red blood
cells that contain HbS become deformed, rigid with loss of
ability to pass through narrow capillaries leading to fre-
quent thrombosis, vascular occlusions, and progressive
organ damage [1].
The aim of this study was to assess serum levels of some
gonadal hormones in 40 female children with HbSS in corre-
lation with iron overload.
In this study, there was significantly higher serum ferritin
and iron levels and significantly lower total iron binding
capacity in Group I compared with Group II. This is inagreement with Akodu et al. [19] and Akinsegun et al. [20]
who found that chronic hemolysis and repeated blood trans-
fusion are the main causes of iron overload in patients with
chronic hemolytic anemia as with the regular blood
transfusion, the equivalent of 100–200 mL of pure red blood
cells per kg per year are transfused, which is equivalent to
108–216 mg of iron per kg body weight per year. Thus, with
regular blood transfusion, iron stores increase to
many times the normal unless regular chelation therapy is
given [21].
In the current study, there was delayed puberty in Group
I compared with Group II with regards to Tanner staging.
This is in agreement with Thomas et al. [22] who stated that
puberty is delayed for about 2 years in boys and girls with
SCA. Serjeant et al. [23] who studied 99 patients with
homozygous SCA, 69 with sickle cell hemoglobin C disease,
and 100 controls with normal hemoglobin genotypes, and
found a delayed mean age of menarche by 0.5 years in sickle
cell hemoglobin C disease and by 2.4 years in homozygous
HbSS. Kyriakou and Skordis [24] stated that hypothalamus
and pituitary damage is progressive in patients with HbSS
with iron overload, even when intensive iron chelation ther-
apy was given and hypogonadism is often unavoidable.
Hypogonadotrophic hypogonadism could be explained
iron toxicity on gonadotroph cells and adipose tissue, with
resulting impaired synthesis of leptin and a decrease in
the physiological role of leptin in sexual maturation and fer-
tility, as leptin levels increase dramatically in early puberty
and stimulate the hypothalamic–pituitary–gonadal axis
[25]. Other possible causes of hypogonadotrophic hypogo-
nadism may include liver disorders, chronic hypoxia, dia-
betes mellitus, and zinc deficiency [26]. Our study showed
that iron overload was a significant cause of hypogonadism
in Group I using univariate analysis.
In the current study, serum levels of LH, FSH, and estro-
gen were significantly lower in Group I compared with Group
II. This is in agreement with Wood et al. [27], Kurtoglu et al.
[28] and Abdulzahra et al. [29] who explained different
endocrine problems in HbSS patients with iron overload by
iron deposition in secretory cell of endocrine glands such
Table 5 Univariate and multivariate analysis of factors affecting hypogonadism.
Factors affecting hypogonadism Univariate p Multivariate
p RR 95% CI
Iron overload (40 cases had iron overload) .002 0.007 2.4 1.5–8.5
Hypothyroidism (3 cases had hypothyroidism) .21 0.23 2.1 1.2–6.5
Diabetes mellitus (2 cases had diabetes mellitus) .32 0.64 3.2 1.6–5.4
Zinc deficiency (6 cases had zinc deficiency) .45 0.34 3.6 1.1–4.9
Note. CI = confidence interval; RR = risk ratio.
6 A.A. Hagag et al.as gonadotrophin cell of the pituitary gland that leads to the
impairment of gonadal hormone secretion including FSH and
LH [27–29]. Also, the ovaries are vulnerable to the toxic
effect of excess iron even if it is not persistent leading to
deficiency of estrogen hormone secretion [26].
In the current study, there were significant negative cor-
relations between serum estrogen, LH, FSH, and serum fer-
ritin levels. This is in agreement with Kyriakou and Skordis
[24]. This could be explained by progressive damage of
the pituitary gland with a subsequent decrease of gonadal
hormones with a progressive increase in iron load.
Conclusion
Female patients with HbSS may have gonadal hormones defi-
ciency with a significant negative correlation between gona-
dal hormones including FSH, LH, estrogen, and serum
ferritin. Recommendations include: (1) regular iron chela-
tion for the prevention of irreversible damage to the ovaries
and attaining normal sexual maturation; and (2) regular fol-
low up for females with HbSS with assessment of puberty, as
they are more vulnerable to develop hypogonadism and may
require hormonal replacement therapy.
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